TRAVASOL 3.5% W/ ELECTROLYTES
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 3.5% W/ ELECTROLYTES (TRAVASOL 3.5% W/ ELECTROLYTES).
TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution providing amino acids (3.5% crystalline amino acids) and electrolytes for protein synthesis and maintenance of electrolyte balance in patients unable to meet nutritional needs enterally. The amino acids serve as substrates for protein synthesis, while electrolytes support cellular function and acid-base balance.
| Metabolism | Amino acids undergo hepatic metabolism via transamination, deamination, and urea cycle; branched-chain amino acids are metabolized in skeletal muscle; electrolytes are excreted or reabsorbed via renal mechanisms. |
| Excretion | Renal: 100% of infused amino acids and electrolytes are excreted renally as urea and electrolytes, respectively. |
| Half-life | Amino acids: ~5–10 min for free amino acids (rapidly cleared from plasma); electrolytes: not applicable as they are distributed and eliminated via homeostasis; clinical context: infusion requires continuous monitoring due to rapid clearance. |
| Protein binding | Amino acids: minimal (<10%) binding to plasma proteins; electrolytes: negligible (e.g., sodium, potassium, calcium are free ions). |
| Volume of Distribution | Amino acids: 0.3–0.5 L/kg (distributes primarily to extracellular fluid); electrolytes: varies by ion (e.g., Na+ 0.6–0.7 L/kg, K+ 4–5 L/kg). Clinical meaning: reflects rapid equilibration with extracellular space. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within minutes) upon infusion initiation for amino acid utilization and electrolyte effects. |
| Duration of Action | Intravenous: 2–4 hours for amino acid elevation after infusion cessation; electrolytes: sustained until balanced by renal excretion. |
| Molecular Weight | Amino acid molecular weights range from 75.07 Da (glycine) to 204.23 Da (tryptophan); the average molecular weight of the mixture is approximately 137 Da. |
Intravenous: 500 mL to 2 L per day as part of total parenteral nutrition; infusion rate adjusted to meet nutritional requirements and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal failure (GFR <30 mL/min) without appropriate electrolyte monitoring; adjust potassium, phosphate, and magnesium based on serum levels; may require reduced volume in moderate to severe impairment. |
| Liver impairment | Use with caution in Child-Pugh class B or C; monitor ammonia, electrolytes, and glucose; avoid branched-chain amino acid formulations; reduce protein content if encephalopathy present. |
| Pediatric use | Dose based on body weight: 1-2 g/kg/day of amino acids; typical infusion rate 0.5-1 mL/kg/hour; adjust electrolytes per serum levels and age-specific requirements. |
| Geriatric use | Start at lower end of adult dose; monitor renal function and fluid status closely; adjust volume to avoid fluid overload; check electrolytes frequently. |
| 1st trimester | No adequate studies in pregnant women. Use only if clearly needed and potential benefit justifies risk. |
| 2nd trimester | No adequate studies in pregnant women. Use only if clearly needed and potential benefit justifies risk. |
| 3rd trimester | Use with caution; monitor for fluid and electrolyte imbalances in the neonate if used near term. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 3.5% W/ ELECTROLYTES (TRAVASOL 3.5% W/ ELECTROLYTES).
| Placental transfer | Amino acids and electrolytes are known to cross the placenta by active transport. Degree of transfer is physiologic and depends on maternal and fetal needs. |
| Breastfeeding | Travasol 3.5% w/ Electrolytes is compatible with breastfeeding. Amino acids and electrolytes are normal constituents of breast milk. Monitor infant for potential adverse effects from excessive intake. |
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | TRAVASOL 3.5% W/ ELECTROLYTES is a parenteral nutrition solution. No teratogenic risk is established; however, use during pregnancy should be based on clinical necessity as malnutrition poses fetal risks. Inadequate nutrition in any trimester can impair fetal growth and development. |
| Fetal Monitoring | Monitor maternal serum electrolytes, blood glucose, fluid balance, and renal function. Fetal monitoring includes assessment of growth and well-being during prolonged use, particularly if maternal nutritional status is compromised. |
| Fertility Effects | No known adverse effects on fertility from TRAVASOL 3.5% W/ ELECTROLYTES. Fertility may be impacted by the underlying condition requiring parenteral nutrition. No specific data available. |
■ FDA Black Box Warning
Not for use in patients with inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria) due to risk of severe metabolic acidosis, hyperammonemia, or neurological injury.
| Serious Effects |
Hypersensitivity to any componentSevere metabolic acidosisHyperammonemiaHepatic coma or severe hepatic insufficiencySevere renal impairment (unless dialyzed)Inborn errors of amino acid metabolism
| Precautions | Risk of metabolic complications including hyperglycemia, hyperammonemia, and azotemia, Fluid overload in patients with renal or cardiac impairment, Electrolyte imbalances: hyperkalemia, hypernatremia, or hypophosphatemia, Intravenous infusion may cause thrombosis or infection, Monitor liver function, serum electrolytes, blood glucose, and acid-base status |
| Food/Dietary | No known direct food interactions; however, patients receiving total parenteral nutrition should follow a prescribed oral diet if tolerated. Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes) without medical advice, as the solution may contain potassium. Monitor fluid and electrolyte intake overall. |
| Clinical Pearls | Verify that the solution does not contain suspended particles or discoloration before administration. Use a dedicated IV line with an in-line filter. Infuse via a central vein to prevent thrombophlebitis; peripheral administration may be used if adequate dilution is maintained. Monitor serum electrolytes, glucose, and fluid balance frequently. Do not add medications to the container without checking compatibility. Use within 24 hours of spiking the bag. In pediatric patients, adjust infusion rate based on body surface area and metabolic needs. |
| Patient Advice | Report any signs of infection at the IV site, such as redness, swelling, or pain. · Inform your healthcare provider if you experience shortness of breath, chest pain, or irregular heartbeat. · Do not adjust the infusion rate yourself; follow the prescribed schedule exactly. · Keep the IV site clean and dry; do not remove the dressing without medical guidance. · Inform your doctor if you have diabetes, kidney disease, or heart failure before starting therapy. · This solution provides nutrition and electrolytes; it is not a substitute for oral food intake. |
Loading safety data…